Paradigm Biopharmaceuticals (ASX:PAR) reports Zilosul reduces pain in knee patients

Company News

by Rachael Jones

Paradigm Biopharmaceuticals (ASX:PAR) report that patients receiving Zilosul reported a reduction in pain.

In the 76 patients treated, 73.7 per cent reported at least a 25 per cent reduction in pain with 52.6 per cent of patients reporting a greater than 50 per cent reduction in pain.

Paradigm released its first set of data using the WOMAC pain scoring index.

The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)™ is a widely used to evaluate the condition of patients with osteoarthritis of the knee and hip, including pain, stiffness, and physical functioning of the joints.

The WOMAC pain score which is a composite of 5 pain subgroups demonstrated pain reductions across patients in; night-time pain (63.7%); sitting (56.1%), standing (49.8%), walking on flat surface (45.6%) and pain on stairs (39.1%).

Shares in Paradigm Biopharmaceuticals (ASX:PAR) are trading 7.9 per cent higher at $2.86.
 

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.